Dr. Hiroto Inaba, MD, PhD

Claim this profile

St. Jude Children's Research Hospital

Studies Acute Myelogenous Leukemia
Studies Leukemia
3 reported clinical trials
25 drugs studied

Area of expertise

1Acute Myelogenous Leukemia
Hiroto Inaba, MD, PhD has run 2 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:
KMT2A positive
NUP98 positive
NPM1 positive
2Leukemia
Hiroto Inaba, MD, PhD has run 1 trial for Leukemia.

Affiliated Hospitals

Image of trial facility.
St Jude Children's Research Hospital

Clinical Trials Hiroto Inaba, MD, PhD is currently running

Image of trial facility.

Venetoclax + Chemotherapy

for Acute Myeloid Leukemia

This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia (AML). Primary Objectives: * Establish the tolerability adding venetoclax to standard chemotherapy in pediatric patients with AML * Estimate the proportion of patients who become minimal residual disease (MRD) negative by flow cytometry after one course of venetoclax-based induction therapy Secondary Objectives: \- Estimate the rates of complete remission (CR), event-free survival (EFS), and overall survival (OS) in pediatric patients who receive venetoclax-based chemotherapy
Recruiting1 award Phase 2
Image of trial facility.

Revumenib + Chemotherapy

for Acute Myeloid Leukemia

This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that did not go into remission after treatment (refractory) or has come back after treatment (relapsed), and to determine the total dose of the 3-drug combination of revumenib, azacitidine and venetoclax that can be given safely in participants also taking an anti-fungal drug. Primary Objective * To determine the safety and tolerability of revumenib + azacitidine + venetoclax in pediatric patients with relapsed or refractory AML or ALAL. Secondary Objectives * Describe the rates of complete remission (CR), complete remission with incomplete count recovery (CRi), and overall survival for patients treated with revumenib + azacitidine + venetoclax at the recommended phase 2 dose (RP2D).
Recruiting1 award Phase 110 criteria

More about Hiroto Inaba, MD, PhD

Clinical Trial Related8 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Hiroto Inaba, MD, PhD has experience with
  • Cytarabine
  • Venetoclax
  • Asparaginase Erwinia Chrysanthemi (recombinant)-rywn
  • Blinatumomab
  • Bortezomib
  • Calaspargase Pegol

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Hiroto Inaba, MD, PhD specialize in?
Is Hiroto Inaba, MD, PhD currently recruiting for clinical trials?
Are there any treatments that Hiroto Inaba, MD, PhD has studied deeply?
What is the best way to schedule an appointment with Hiroto Inaba, MD, PhD?
What is the office address of Hiroto Inaba, MD, PhD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security